These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31724253)

  • 1. Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus.
    Heise T; Donnelly C; Barve A; Aubonnet P
    Diabetes Obes Metab; 2020 Apr; 22(4):521-529. PubMed ID: 31724253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study.
    Hövelmann U; Raiter Y; Chullikana A; Liu M; Donnelly C; Lawrence T; Sengupta N; Cl G; Ranganna G; Barve A
    Diabetes Obes Metab; 2021 Dec; 23(12):2670-2678. PubMed ID: 34378861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins.
    Chen W; Lu J; Plum-Mörschel L; Andersen G; Zijlstra E; He A; Xie T; Li L; Hao C; Gan Z; Heise T
    Diabetes Obes Metab; 2023 Dec; 25(12):3817-3825. PubMed ID: 37735841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.
    Blevins TC; Barve A; Sun B; Ankersen M
    Diabetes Obes Metab; 2018 Aug; 20(8):1944-1950. PubMed ID: 29656504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.
    Sun B; Sengupta N; Rao A; Donnelly C; Waichale V; Roy AS; Ramaswamy S; Pathak D; Bowsher RR; Raiter Y; Aubonnet P; Barve A
    BMC Endocr Disord; 2021 Jun; 21(1):129. PubMed ID: 34174848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
    Crutchlow MF; Palcza JS; Mostoller KM; Mahon CD; Barbour AM; Marcos MC; Xu Y; Watkins E; Morrow L; Hompesch M
    Diabetes Obes Metab; 2018 Feb; 20(2):400-408. PubMed ID: 28817223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.
    Andersen G; Singh G; Murugesan SMN; Gogineni R; Sharma N; Panda J; Marwah A; Loganathan S; Athalye SN
    Diabetes Obes Metab; 2023 Jun; 25(6):1485-1494. PubMed ID: 36708333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin® R formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study.
    Plum-Mörschel L; Singh G; Murugesan SMN; Marwah A; Panda J; Loganathan S; Athalye SN
    Diabetes Obes Metab; 2022 Apr; 24(4):713-721. PubMed ID: 34981621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study.
    Blevins TC; Barve A; Raiter Y; Aubonnet P; Athalye S; Sun B; Muniz R
    Diabetes Obes Metab; 2020 Mar; 22(3):365-372. PubMed ID: 31691472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.
    Plum-Mörschel L; Klein O; Singh G; Murugesan SMN; Marwah A; Sharma N; Panda J; Loganathan S; Lakshmi GC; Athalye SN
    Diabetes Obes Metab; 2022 Sep; 24(9):1819-1828. PubMed ID: 35589611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study.
    Blevins TC; Barve A; Sun B; Raiter Y; Aubonnet P; Muniz R; Athalye S; Ankersen M
    Diabetes Obes Metab; 2019 Jan; 21(1):129-135. PubMed ID: 30112792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine.
    Goyal P; Pai HV; Kodali P; Vats B; Vajpai N; Annegowda S; Mane K; Mohan S; Saxena S; Veerabhadraia AB; Palande M; Nair PS; More DC; Karudumpa UR; Jyothirmai K; Bhattacharya A; Almeida F; Khyade SG; Gouda S; Ranayhossaini DJ; Moole PR; Smith JP; Barve A; Melarkode R; Ullanat R
    PLoS One; 2021; 16(6):e0253168. PubMed ID: 34133466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
    Kapitza C; Nowotny I; Lehmann A; Bergmann K; Rotthaeuser B; Nosek L; Becker RHA
    Diabetes Obes Metab; 2017 May; 19(5):622-627. PubMed ID: 27987252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes.
    Kapitza C; Nosek L; Schmider W; Teichert L; Nowotny I
    Diabetes Technol Ther; 2020 Apr; 22(4):278-284. PubMed ID: 31825248
    [No Abstract]   [Full Text] [Related]  

  • 15. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
    Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ
    Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus
    Bhatia A; Tawade S; Mastim M; Kitabi EN; Gopalakrishnan M; Shah M; Yeshamaina S; Gobburu J; Sahib M; Thakur D; Prasanna Kumar KM
    Acta Diabetol; 2018 May; 55(5):461-468. PubMed ID: 29453671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.
    Hummel M; Bosje T; Shaw A; Liu MS; Barve A; Kothekar M; Socinski MA; Waller CF
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):487-496. PubMed ID: 33866430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication.
    Vencio S; Caiado-Vencio R; Caixeta LF; Masierek M; Mlynarski W; Drzewoski J; Gregory JM
    Diabetes Obes Metab; 2022 Aug; 24(8):1544-1552. PubMed ID: 35441466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
    Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
    Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.